Skip to main content
Clinical Trials/NCT04507230
NCT04507230
Completed
Not Applicable

Assessment of COVID-19 Associated Coagulopathy and Hypercoagulable State in Upper Egypt

Assiut University1 site in 1 country106 target enrollmentAugust 7, 2020
ConditionsCoagulopathy

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Coagulopathy
Sponsor
Assiut University
Enrollment
106
Locations
1
Primary Endpoint
Thrombophilia screen
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

Coagulopathy is one of the most significant prognostic factors in patients with COVID-19 and is associated with increased mortality and admission to critical care. Most commonly observed coagulopathy in patients hospitalized with COVID-19 (COVID-19-associated coagulopathy) is characterized by increased D-dimer and fibrinogen levels. 71% of patients who did not survive hospitalization reported to have developed disseminated intravascular coagulation (DIC) compared to 0.6% of survivors.

Detailed Description

studying the detailed coagulation screen and second line coagulation parameters including both thrombophilia screen and other acute phase coagulation factors.

Registry
clinicaltrials.gov
Start Date
August 7, 2020
End Date
October 31, 2020
Last Updated
5 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Azza Abdelaal

lecturer of clinical pathology

Assiut University

Eligibility Criteria

Inclusion Criteria

  • patients with COVID 19 positive by RT- PCR

Exclusion Criteria

  • no exclusions

Outcomes

Primary Outcomes

Thrombophilia screen

Time Frame: 1 month

Full thrombophilia screen

VWF, FVIII

Time Frame: 1 month

VWFAg, FVIII

Coagulation screen

Time Frame: 1 month

Full coagulation screen

Study Sites (1)

Loading locations...

Similar Trials